keyword
MENU ▼
Read by QxMD icon Read
search

Hepatitis c genotype 4

keyword
https://www.readbyqxmd.com/read/28543275/the-role-of-itpa-and-ribavirin-transporter-genes-polymorphisms-in-prediction-of-ribavirin-induced-anemia-in-chronic-hepatitis-c-egyptian-patients
#1
Ehab S El Desoky, Alaa T Abdelhafez, Jessica Cusato, Sherif I Kamel, Abeer M R Hussein, Amedeo De Nicolo, Giovanni Di Perri, Antonio D'Avolio
Few data are available concerning the roles of polymorphisms of inosine triphosphatase (ITPA) gene and ribavirin (RBV) transporter genes in the prediction of RBV-induced anemia among Egyptians with chronic hepatitis C (CHC). Genotyping of 3 ITPA gene variants and 2 variants of RBV transporter genes has been performed in 123 patients under pegylated interferon-α/ribavirin treatment. The baseline hemoglobin and ITPA rs1127354 CA/AA have been found as predictors of anemia at 4, 8 and 12 weeks of RBV therapy. In addition, ITPA rs7270101 AC/CC and age predicted anemia after 12 weeks of therapy...
May 24, 2017: Clinical and Experimental Pharmacology & Physiology
https://www.readbyqxmd.com/read/28539950/association-of-changes-in-mood-status-and-psychosocial-well-being-with-depression-during-interferon-based-treatment-for-hepatitis-c
#2
Jung-Seok Choi, Won Kim, Bo Kyung Sohn, Jun-Young Lee, Hee Yeon Jung, Sohee Oh, Sae Kyoung Joo, Hwi Young Kim, Yong Jin Jung
OBJECTIVE: The aims of this prospective study were to investigate temporal changes in mood status and distress level, as well as the development of depression, during pegylated interferon (PEG-IFN)-based treatment of patients with chronic hepatitis C (CHC). We also explored whether baseline demographic, psychiatric, and personality traits predicted the evolution of depression. METHODS: CHC patients without depression were screened with laboratory tests; psychiatric interviews; and evaluations of mood symptoms, level of distress, and personality traits...
May 2017: Psychiatry Investigation
https://www.readbyqxmd.com/read/28534541/-effectiveness-of-second-generation-direct-acting-antivirals-in-chronic-hepatitis-c
#3
R Juanbeltz Zurbano, J M Zozaya Urmeneta, J Repáraz Padrós, J Castilla Catalán, M T Sarobe Carricas, J I Úriz-Otano, M Gracia Ruiz de Alda, R San Miguel Elcano
BACKGROUND: Second-generation direct-acting antivirals (DAA) have shown high sustained virologic response (SVR) for the treatment of chronic hepatitis C in clinical trials. The objective of this study is to estimate DAA effectiveness in treatment of this disease. METHODS: Hepatitis C virus (HCV) monoinfected patients and HCV-human immunodeficiency virus (HIV) coinfected pa-tients who started interferon-free DAA based regimens during 2015 were included. The primary effectiveness outcome was SVR, defined as an undetectable viral load 12 weeks after the end of treatment...
April 30, 2017: Anales del Sistema Sanitario de Navarra
https://www.readbyqxmd.com/read/28533924/interferon-free-treatments-in-patients-with-hepatitis-c-genotype-1-4-infections-in-a-real-world-setting
#4
Huascar Ramos, Pedro Linares, Ester Badia, Isabel Martín, Judith Gómez, Carolina Almohalla, Francisco Jorquera, Sara Calvo, Isidro García, Pilar Conde, Begoña Álvarez, Guillermo Karpman, Sara Lorenzo, Visitación Gozalo, Mónica Vásquez, Diana Joao, Marina de Benito, Lourdes Ruiz, Felipe Jiménez, Federico Sáez-Royuela, Asociación Castellano Y Leonesa de Hepatología ACyLHE
AIM: To investigated the real-world effectiveness and safety of various regimens of interferon-free treatments in patients infected with hepatitis C virus (HCV). METHODS: We performed an observational study to analyze different antiviral treatments administered to 462 HCV-infected patients, of which 56.7% had liver cirrhosis. HCV RNA after 4 wk of treatment and at 12 wk after treatment sustained virologic response (SVR) as well as serious adverse events (SAEs) was analyzed first for the whole cohort and then separately in patients who met or did not meet the inclusion criteria of a clinical trial (CT-met and CT-unmet, respectively)...
May 6, 2017: World Journal of Gastrointestinal Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28532708/high-hepatitis-c-viral-load-and-genotype-2-are-strong-predictors-of-chronic-kidney-disease
#5
Tai-Shuan Lai, Mei-Hsuan Lee, Hwai-I Yang, San-Lin You, Sheng-Nan Lu, Li-Yu Wang, Yong Yuan, Gilbert L'Italien, Kuo-Liong Chien, Chien-Jen Chen
Associations between chronic hepatitis C virus (HCV) infection and chronic kidney disease (CKD) remain controversial. Here we aimed to clarify the association between HCV viral load, genotype, and CKD in 13,805 participants aged 30-65 years enrolled in the REVEAL-HCV Study, a community-based prospective study conducted in 1991-1992. CKD was defined by consecutive proteinuria or an estimated glomerular filtration rate (eGFR) under 60 mL/min/1.73 m(2). Chronic HCV infection was defined by detectable HCV viral load...
May 20, 2017: Kidney International
https://www.readbyqxmd.com/read/28527244/-hepatitis-c-virus-genotypes-circulating-in-colombia
#6
Óscar Santos, Alberto Gómez, Viviana Vizcaíno, María Consuelo Casas, María Del Pilar Ramírez, Patricia Olaya
INTRODUCTION: Chronic hepatitis C virus infection is a worldwide public health problem; it has been estimated that over 180 million people are infected with this virus worldwide. Its precise incidence and prevalence (i.e., epidemiology) and the most frequent circulating genotypes in Colombia are unknown. OBJECTIVE: To describe the hepatitis C virus (HCV) genotypes and subtypes in infected Colombian patients. MATERIALS AND METHODS: We recovered the data on 1,538 HCV isolates from 1,527 patients in two Colombian reference laboratories typed by PAGE or qPCR...
January 24, 2017: Biomédica: Revista del Instituto Nacional de Salud
https://www.readbyqxmd.com/read/28521955/prevalence-of-relevant-ns5a-resistance-associated-substitutions-to-elbasvir-in-genotype-1a-hepatitis-c-virus-patients-in-spain
#7
Claudia Palladino, Beatriz Esteban-Cartelle, Irene Mate-Cano, Marta Sánchez-Carrillo, Salvador Resino, Verónica Briz
Resistance-associated substitutions (RASs) to the new HCV NS5A inhibitor elbasvir may limit its efficacy and lead to virological failure in HCV-GT1a-infected patients. There are no data outside clinical trials evaluating their prevalence and impact in grazoprevir/elbasvir in GT1a-infected patients in Spain. A multicentre cross-sectional study of 632 initial patients was conducted. In 13 of these patients, the sample could not be amplified or a consensus sequence by Sanger sequencing could not be performed. Ultimately, 617 HCV-G1a-infected individuals treated at 84 Spanish hospitals from the 17 autonomous communities plus the 2 autonomous cities of Spain were analysed...
May 15, 2017: Enfermedades Infecciosas y Microbiología Clínica
https://www.readbyqxmd.com/read/28521213/phylogenetic-analysis-of-an-epidemic-outbreak-of-acute-hepatitis-c-in-hiv-infected-patients-by-ultra-deep-pyrosequencing
#8
Noelia Caro-Pérez, María Martínez-Rebollar, Josep Gregori, Josep Quer, Patricia González, Martina Gambato, Neris García-González, Fernando González-Candelas, Josep Costa, Juan Ignacio Esteban, Josep Mallolas, Xavier Forns, Montse Laguno, Sofía Pérez-Del-Pulgar
BACKGROUND: The incidence of acute hepatitis C (AHC) among HIV-infected men who have sex with men (MSM) has increased significantly in the last 10 years. Several studies point to a social and sexual network of HIV-positive MSM that extends internationally. OBJECTIVES: The aim of our study was to investigate the dynamics of HCV transmission in an outbreak of AHC in HIV-infected MSM in Barcelona by ultra-deep pyrosequencing. STUDY DESIGN: Between 2008 and 2013, 113 cases of AHC in HIV-infected MSM were diagnosed in the Infectious Diseases Unit, Hospital Clínic, Barcelona...
May 10, 2017: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
https://www.readbyqxmd.com/read/28521211/hepatitis-c-virus-core-antigen-a-simplified-treatment-monitoring-tool-including-for-post-treatment-relapse
#9
François M J Lamoury, Angelica Soker, Danica Martinez, Behzad Hajarizadeh, Evan B Cunningham, Philip Cunningham, Philip Bruggmann, Graham R Foster, Olav Dalgard, Markus Backmund, Brian Conway, Geert Robaeys, Tracy Swan, Gavin Cloherty, Pip Marks, Jason Grebely, Gregory J Dore, Tanya L Applegate
BACKGROUND: Simple, affordable diagnostic tools are essential to facilitate global hepatitis C virus (HCV) elimination efforts. OBJECTIVES: This study evaluated the clinical performance of core antigen (HCVcAg) assay from plasma samples to monitor HCV treatment efficacy and HCV viral recurrence. STUDY DESIGN: Plasma samples from a study of response-guided pegylated-interferon/ribavirin therapy for people who inject drugs with chronic HCV genotype 2/3 infection were assessed for HCV RNA (AmpliPrep/COBAS Taqman assay, Roche) and HCVcAg (ARCHITECT HCV Ag, Abbott Diagnostics) during and after therapy...
May 11, 2017: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
https://www.readbyqxmd.com/read/28511425/early-experience-of-sofosbuvir-based-combination-therapy-in-real-life-cohort-with-chronic-hepatitis-c-infection
#10
Rajiv Mehta, Mayank Kabrawala, Subhash Nandwani, Rini Tekriwal, Payal Nandania
INTRODUCTION: There is scarcity of data in literature regarding the treatment response with Sofosbuvir (SOF) based therapy in Indian patients with chronic Hepatitis-C Virus (HCV) infection. AIM: This study was designed to observe initial treatment response to SOF based therapy in a "real-life" cohort of Indian patients with HCV infection. MATERIALS AND METHODS: This is a prospective, observational and single center study. A total of 107 patients who were diagnosed with chronic HCV infection and received SOF based treatment between March 2015 and December 2015 were included...
March 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28509128/a-case-of-rapid-amelioration-of-hepatitis-c-virus-associated-cryoglobulinemic-membranoproliferative-glomerulonephritis-treated-by-interferon-free-directly-acting-antivirals-for-hcv-in-the-absence-of-immunosuppressant
#11
Fumiaki Obata, Taichi Murakami, Junko Miyagi, Sayo Ueda, Taizo Inagaki, Masanori Minato, Hiroyuki Ono, Kenji Nishimura, Eriko Shibata, Masanori Tamaki, Sakiya Yoshimoto, Fumi Kishi, Seiji Kishi, Motokazu Matsuura, Kojiro Nagai, Hideharu Abe, Toshio Doi
Mixed cryoglobulinemic syndrome, which is a systemic vasculitis characterized by the immune complex deposition in small- and medium-sized arteries and most often due to chronic hepatitis C virus (HCV) infection, sometimes clinically manifests as refractory glomerulonephritis or nephritic syndrome. Patients with mixed cryoglobulinemic nephropathy who have a rapidly progressive glomerulonephritis should receive immunosuppressive therapy. After disease stabilization, patients should receive concurrent therapy for the underlying HCV infection...
May 2017: CEN Case Reports
https://www.readbyqxmd.com/read/28507583/intravenous-drug-use-an-independent-predictor-for-hcv-genotypes-3-and-4-infection-among-hiv-hcv-co-infected-patients
#12
Dubravka Salemovic, Ivana Pesic-Pavlovic, Djordje Jevtovic, Ksenija Bojovic, Jovan Ranin, Branko Brmbolic, Maja Stanojevic
INTRODUCTION: About one quarter of human immunodeficiency virus (HIV) infected persons in Serbia have also been found to be hepatitis C virus (HCV) co-infected. In the general population, HCV genotype 1 has been shown to be the most prevalent one. Here, we present the first study on the distribution of HCV genotypes among HIV/HCV co-infected patients in Serbia, in relation to epidemiological and clinical features. MATERIAL AND METHODS: The study included HIV/HCV co-infected and a group of HCV mono-infected patients in the period 1998-2012, with collection of epidemiological, clinical, and behavioral data using a standardized questionnaire...
April 1, 2017: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/28506030/simeprevir-based-triple-therapy-with-reduced-doses-of-pegylated-interferon-%C3%AE-2a-plus-ribavirin-for-interferon-ineligible-patients-with-genotype-1b-hepatitis-c-virus
#13
Hideyuki Tamai, Yoshiyuki Ida, Akira Kawashima, Naoki Shingaki, Ryo Shimizu, Kosaku Moribata, Tetsushi Nasu, Takao Maekita, Mikitaka Iguchi, Jun Kato, Taisei Nakao, Masayuki Kitano
Background/Aims: The present study aimed to evaluate the safety and efficacy of simeprevir-based triple therapy with reduced doses of pegylated interferon (PEG-IFN) and ribavirin for interferon (IFN) ineligible patients, such as elderly and/or cirrhotic patients, and to elucidate the factors contributing to a sustained virologic response (SVR). Methods: One hundred IFN ineligible patients infected with genotype 1b hepatitis C virus (HCV) were treated. Simeprevir (100 mg) was given orally together with reduced doses of PEG-IFN-α 2a (90 μg), and ribavirin (200 mg less than the recommended dose)...
May 17, 2017: Gut and Liver
https://www.readbyqxmd.com/read/28504962/association-of-stat4-and-ptpn22-polymorphisms-and-their-interactions-with-type-1-autoimmune-hepatitis-susceptibility-in-chinese-han-children
#14
Xiaofeng Li, Huiqin Chen, Yun Cai, Pingping Zhang, Zhuanggui Chen
AIMS: To investigate the impact of signal transducer and activator of transcription 4 (STAT4) and the protein tyrosine phosphatase N22 (PTPN22) gene single nucleotide polymorphisms (SNPs), gene- gene interactions and haplotype on type-1 Autoimmune Hepatitis (AIH) risk. RESULTS: Logistic regression analysis showed that type 1 AIH was significantly higher in carriers of T allele of rs7574865 than those with GG genotype (P- value less than 0.001), higher in carriers of C allele of rs7582694 than those with GG genotype (P- value < 0...
April 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28504842/safety-and-efficacy-of-current-daa-regimens-in-kidney-and-liver-transplant-recipients-with-hepatitis-c-results-from-the-hcv-target-study
#15
Varun Saxena, Vandana Khungar, Elizabeth C Verna, Josh Levitsky, Robert S Brown, Mohamed A Hassan, Mark S Sulkowski, Jacqueline G O'Leary, Farrukh Koraishy, Joseph S Galati, Alexander A Kuo, Monika Vainorius, Lucy Akushevich, David R Nelson, Michael W Fried, Norah Terrault, K Rajender Reddy
BACKGROUND: Data outside of clinical trials with direct acting antiviral (DAA) regimens with or without ribavirin as treatment of chronic HCV in solid organ transplant recipients is limited. METHODS: Liver transplant (LT), kidney transplant (KT) and dual liver kidney (DLK) transplant recipients from the HCV-TARGET database, a multicenter, longitudinal clinical care treatment cohort, treated with DAA regimens between January 1 2014 and February 15, 2016 were included to assess safety and efficacy...
May 15, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28497758/ombitasvir-paritaprevir-and-ritonavir-with-or-without-dasabuvir-plus-ribavirin-for-patients-with-hepatitis-c-virus-genotype-1-or-4-infection-with-cirrhosis-abacus-a-prospective-observational-study
#16
Salvatore Petta, Marco Marzioni, Pierluigi Russo, Alessio Aghemo, Alfredo Alberti, Antonio Ascione, Andrea Antinori, Raffaele Bruno, Savino Bruno, Antonio Chirianni, Giovanni Battista Gaeta, Edoardo G Giannini, Manuela Merli, Vincenzo Messina, Simona Montilla, Carlo Federico Perno, Massimo Puoti, Giovanni Raimondo, Maria Rendina, Francesca Ceccherini Silberstein, Erica Villa, Anna Linda Zignego, Luca Pani, Antonio Craxì
BACKGROUND: We ran a compassionate use nationwide programme (ABACUS) to provide access to ombitasvir, paritaprevir, and ritonavir, with dasabuvir, plus ribavirin for hepatitis C virus (HCV) genotype 1 infection and ombitasvir, paritaprevir, and ritonavir, plus ribavirin for HCV genotype 4 infection in patients with cirrhosis at high risk of decompensation while approval of these regimens was pending in Italy. METHODS: In this prospective observational study, we collected data from a compassionate use nationwide programme from March 17, 2014, to May 28, 2015...
June 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28497489/efficacy-and-safety-of-telaprevir-with-natural-human-interferon-beta-and-ribavirin-in-japanese-chronic-hepatitis-c-patients-with-depression
#17
Hiromitsu Kumada, Satoshi Mochida, Makoto Nakamuta, Fumitaka Suzuki, Takashi Yagi, Ryuji Takasaki, Masao Okai, Naohiro Kamiya, Yasushi Okada, Saya Hirota, Madori Orihashi, Miyoko Ochi, Kazuaki Chayama
AIMS: To assess the efficacy and safety of telaprevir (TVR) when used in combination with natural human interferon-beta (IFN-beta) and ribavirin (RBV) for the genotype 1 patients with depression as compared to the IFN-beta/RBV therapy in Japan. We also examined the efficacy of the TVR/IFN-beta/RBV therapy in treatment failure genotype 2 patients with depression. METHODS: For the genotype 1 patients, 30 patients received TVR (750 mg every 8 h) for 12 weeks combination with IFN-beta and RBV for 24 weeks (Group A), and 30 received IFN-beta and RBV for 48 weeks (Group B)...
May 11, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28496530/assessment-of-the-relation-between-snp-in-mxa-gene-and-the-responsiveness-of-egyptian-hcv-genotype-4-patients-to-pegylated-interferon-and-ribavirin-treatment
#18
Mohamed Hassany, Amany Gamal, Nashwa Zaki, Basem Eysa
BACKGROUND: Pegylated interferon (PegIFN) is used in the treatment of chronic hepatitis C virus (HCV) patients especially in resource limited countries. Treatment with PegIFN stimulates the expression of a number of host genes encoding enzymes with antiviral activities, including myxovirus resistance gene-A (MxA gene). MxA gene was found to have a single nucleotide polymorphism (SNP) at position -88 in the promoter region that affects the expression of MxA gene protein and was suggested to affect the treatment outcome...
April 2017: Gastroenterology Research
https://www.readbyqxmd.com/read/28489763/naturally-occurring-drug-resistance-associated-variants-to-hepatitis-c-virus-direct-acting-antiviral-agents-in-treatment-naive-hcv-genotype-1b-infected-patients-in-china
#19
Zhanyi Li, Ying Zhang, Ying Liu, Xiaoqiong Shao, QiuMin Luo, Qingxian Cai, Zhixin Zhao
The direct-acting antiviral agents (DAAs) have drastically improved the prognosis of hepatitis C virus (HCV) patients. However, the resistance-associated variants (RAVs) to DAAs may hamper treatment. There was a lack of data on the prevalence of pre-exist RAVs in Chinese HCV-infected patients. We performed nested PCR assays on 74 HCV genotype 1b-infected patients to amplify HCV viral regions of NS3, NS5A, and NS5B to investigate the prevalence of RAVs to DAAs in treatment-naive HCV genotype1b-infected patients in China...
May 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28482405/-efficacy-and-safety-of-pegylated-interferon-%C3%AE-2b-injection-y-shape-40-kd-in-treatment-of-patients-with-genotype-1-6-chronic-hepatitis-c
#20
B Feng, J Shang, S H Wu, H Chen, Y Han, Y Q Li, D Z Zhang, L F Zhao, S F Wei, Q Mao, C B Yin, T Han, M R Wang, S J Chen, J Li, Q Xie, Z Zhen, Z L Gao, Y X Zhang, G Z Gong, D L Yang, C Pan, J F Sheng, H Tang, Q Ning, G F Shi, J Q Niu, G H Luo, Y T Sun, H You, G Q Wang, L L Zhang, J Peng, Q Zhang, J J Liu, C W Chen, X Y Chen, W Zhao, R H Wang, L Sun, L Wei
Objective: To investigate the efficacy and safety of the new investigational drug pegylated interferon α-2b (Peg-IFN-α-2b) (Y shape, 40 kD) injection (180 µg/week) combined with ribavirin in the treatment of patients with genotype 1/6 chronic hepatitis C (CHC), with standard-dose Peg-IFN-α-2a combined with ribavirin as a positive control. Methods: A multicenter, randomized, open-label, and positive-controlled phase III clinical trial was performed. Eligible patients with genotype 1/6 CHC were screened out and randomly divided into Peg-IFN-α-2b(Y shape, 40kD) group and Peg-IFN-α-2a group at a ratio of 2:1...
March 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
keyword
keyword
86765
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"